Advertisement
U.S. markets open in 3 hours 9 minutes

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.1750-0.1850 (-5.51%)
At close: 04:00PM EDT
3.1600 -0.01 (-0.47%)
Pre-Market: 05:39AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.3600
Open3.3400
Bid2.1400 x 1300
Ask2.1300 x 4000
Day's Range3.0000 - 3.3600
52 Week Range1.6400 - 3.7400
Volume22,910,036
Avg. Volume10,744,215
Market Cap1.734B
Beta (5Y Monthly)0.55
PE Ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GERN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Geron Corporation
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    23 hours agoArgus Research
View more
  • Yahoo Finance Video

    Geron, Madrigal Pharmaceuticals jump on good news from FDA

    Shares of both Geron (GERN) and Madrigal Pharmaceuticals (MDGL) are soaring after receiving positive news from the Food and Drug Administration. For Geron, an FDA advisory panel backed its blood disorder treatment. For Madrigal, the FDA approved its treatment for a liver disease known as nonalcoholic steatohepatitis, or NASH. Yahoo Finance's Josh Lipton and Julie Hyman discuss the stocks' reaction in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.

  • The Wall Street Journal

    Stocks to Watch Friday: Adobe, Ulta, Fisker

    [**Adobe (ADBE)**](https://www.wsj.com/market-data/quotes/ADBE): The software company's latest results topped forecasts, but guidance for its current quarter [disappointed investors](https://www.wsj.com/livecoverage/stock-market-today-dow-jones-03-15-2024/card/adobe-reports-solid-earnings-but-stock-sinks-after-outlook-underwhelms-investors-fg7wmoXAIxD5cpqyO7v8).

  • Zacks

    Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

    Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.